HOUSTON , TEXAS April 3, 2006. Pharm-Olam International Ltd. (POI), a multi-national CRO to pharmaceutical, biotechnology and medical device industries, announces the addition of new Business Development staff with substantial clinical experience. "Having a sales team that truly understands the language and business of our sponors is a valuable asset to Pharm-Olam", said Iain Gordon, Director of Global Business Development, "Clear communication from the start of a proposal leads to a faster start up and success across the trial's duration." Matt Love was appointed Director of Business Development (U.S. East Coast and Midwest ). He joins Pharm-Olam from Charles Rivers Labs, where he served as a BD executive. He has held several positions outside of sales in the pharma industry including, Clinical Data Coordinator (Covance, ICON), and Quality Assurance Associate with (Rhone-Pulenc Rorer, now Aventis). Matt has successfully completed over $90 million in contracts over his career. Tony Dean was appointed Director of Business Development (U.K.). He has worked as a Clinical Research Associate, and gained over ten years of experience working in Clinical Operations and Project Management before moving into Business Development. Tony has worked with a wide spectrum of CROs, ranging from full service to specialty CROs. He joins Pharm-Olam from Charles River Labs. For further information about Pharm-Olam please contact John Hovre at jhovre@pharm-olam.com. About Pharm-Olam International |